October 8, 2010 – Siemens PETNET Solutions has expanded its imaging biomarker capabilities in Nottingham, England and can now produce new biomarkers as investigational medicine products (IMP) in the United Kingdom.
The IMPs include a hypoxic agent that can identify tumor tissues with low oxygen supply and an amyloid agent for PET imaging of ß-amyloid deposits in the brain.
For more information: www.siemens.com/healthcare
Sept. 26, 2025 — A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently ...
October 03, 2025 
Sept. 20, 2025 — A promising new PET tracer can visualize a protein that is commonly overexpressed in triple-negative ...
September 18, 2025 
May 5, 2025 — GE HealthCare recently announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance ...
May 06, 2025 
July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...
July 30, 2024 
July 25, 2024 — NorthStar Medical Radioisotopes, LLC and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc ...
July 25, 2024 
July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...
July 25, 2024 
June 21, 2024 — The American Society for Radiation Oncology (ASTRO) announced today that following a nationwide search ...
June 21, 2024 
June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...
June 14, 2024 
June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...
June 14, 2024 
June 13, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted more than 8,000 physicians ...
June 13, 2024 